184 related articles for article (PubMed ID: 32149829)
1. Tumoral Melanosis in the Setting of Targeted Immunotherapy for Metastatic Melanoma-A Single Institutional Experience and Literature Review.
Jurgens A; Guru S; Guo R; Brewer J; Bridges A; Jakub J; Comfere N
Am J Dermatopathol; 2021 Jan; 43(1):9-14. PubMed ID: 32149829
[TBL] [Abstract][Full Text] [Related]
2. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
Woodbeck R; Metelitsa AI; Naert KA
Am J Dermatopathol; 2018 Jul; 40(7):523-526. PubMed ID: 29924748
[TBL] [Abstract][Full Text] [Related]
3. Tumoral melanosis after immunotherapy with pembrolizumab - a response sign mimicking melanoma.
Relvas M; Alves F; Mariano A; Cardoso J; Coutinho I
Dermatol Online J; 2020 Oct; 26(10):. PubMed ID: 33147666
[TBL] [Abstract][Full Text] [Related]
4. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
5. Tumoral Melanosis Associated with Pembrolizumab-Treated Metastatic Melanoma.
Bari O; Cohen PR
Cureus; 2017 Feb; 9(2):e1026. PubMed ID: 28348944
[TBL] [Abstract][Full Text] [Related]
6. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
[TBL] [Abstract][Full Text] [Related]
7. Extensive tumoral melanosis associated with ipilimumab-treated melanoma.
Staser K; Chen D; Solus J; Rosman IS; Schaffer A; Cornelius L; Linette GP; Fields RC
Br J Dermatol; 2016 Aug; 175(2):391-3. PubMed ID: 26877232
[TBL] [Abstract][Full Text] [Related]
8. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
Samlowski W; Adajar C
BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
[TBL] [Abstract][Full Text] [Related]
9. Peritoneal melanosis associated with metastatic melanoma previously treated with targeted and immune checkpoint inhibitor therapy.
Sim KK; Connell K; Bhandari M; Paton D
BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33431461
[TBL] [Abstract][Full Text] [Related]
10. Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma.
Pokorny R; McPherson JP; Haaland B; Grossmann KF; Luckett C; Voorhies BN; Sageser DS; Wallentine J; Tolman Z; Hu-Lieskovan S; Swami U
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500258
[TBL] [Abstract][Full Text] [Related]
11. Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma.
Perier-Muzet M; Gatt E; Péron J; Falandry C; Amini-Adlé M; Thomas L; Dalle S; Boespflug A
JAMA Dermatol; 2018 Jan; 154(1):82-87. PubMed ID: 29214290
[TBL] [Abstract][Full Text] [Related]
12. Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study.
Matsuya T; Nakamura Y; Matsushita S; Tanaka R; Teramoto Y; Asami Y; Uehara J; Aoki M; Yamamura K; Nakamura Y; Fujisawa Y; Livingstone E; Zimmer L; Schadendorf D; Kagamu H; Fujimoto M; Honma M; Ishida-Yamamoto A; Araki R; Yamamoto A
J Dermatol; 2020 Jun; 47(6):629-635. PubMed ID: 32275100
[TBL] [Abstract][Full Text] [Related]
13. [Cutaneous regressing/regressed malignant melanoma: a clinicopathologic analysis of 8 cases].
Shen XX; Kong YY; Dai B; Cai X; Wang LW; Kong JC
Zhonghua Bing Li Xue Za Zhi; 2013 Oct; 42(10):675-8. PubMed ID: 24433730
[TBL] [Abstract][Full Text] [Related]
14. Metastatic melanoma: a regional review and future directions.
Khan KH; Goody RB; Hameed H; Jalil A; Coyle VM; McAleer JJ
Tumori; 2012; 98(5):575-80. PubMed ID: 23235751
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
16. Tumoral melanosis involving the sentinel lymph nodes: a case report.
Satzger I; Völker B; Kapp A; Gutzmer R
J Cutan Pathol; 2007 Mar; 34(3):284-6. PubMed ID: 17302615
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
Wagner NB; Lenders MM; Kühl K; Reinhardt L; André F; Dudda M; Ring N; Ebel C; Stäger R; Zellweger C; Lang R; Paar M; Gussek P; Richtig G; Stürmer SH; Kimeswenger S; Oellinger A; Forschner A; Leiter U; Weide B; Gassenmaier M; Schraag A; Klumpp B; Hoetzenecker W; Berking C; Richtig E; Ziemer M; Mangana J; Terheyden P; Loquai C; Nguyen VA; Gebhardt C; Meier F; Diem S; Cozzio A; Flatz L; Röcken M; Garbe C; Eigentler TK
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986126
[TBL] [Abstract][Full Text] [Related]
18. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.
Hua C; Boussemart L; Mateus C; Routier E; Boutros C; Cazenave H; Viollet R; Thomas M; Roy S; Benannoune N; Tomasic G; Soria JC; Champiat S; Texier M; Lanoy E; Robert C
JAMA Dermatol; 2016 Jan; 152(1):45-51. PubMed ID: 26501224
[TBL] [Abstract][Full Text] [Related]
19. Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report.
Langan EA; Budner K; Zillikens D; Terheyden P
Medicine (Baltimore); 2021 Apr; 100(16):e25513. PubMed ID: 33879687
[TBL] [Abstract][Full Text] [Related]
20. Lymph node melanosis from a primary cutaneous lesion combining a nodular (tumoral) melanosis and a congenital dermal melanocytic nevus.
Rongioletti F; Pavesi A; Carli C; Parodi A; Fiocca R
Am J Dermatopathol; 2012 Aug; 34(6):653-7. PubMed ID: 22456514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
